Australia markets close in 1 hour 56 minutes

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
24.14-1.32 (-5.18%)
At close: 04:00PM EST
23.70 -0.44 (-1.82%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close25.46
Open25.93
Bid23.70 x 3200
Ask25.45 x 1800
Day's range23.80 - 26.40
52-week range9.53 - 70.29
Volume1,046,018
Avg. volume1,478,649
Market cap1.691B
Beta (5Y monthly)1.77
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

    -- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. This approval follows the U.S. Food and Drug Administrati

  • GlobeNewswire

    ChemoCentryx to Present at Two Upcoming Investor Conferences

    SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan Healthcare ConferenceWednesday, January 12 at 4:30 p.m. Eastern Time H.C. Wainwright Virtual BioConnect ConferenceOn-demand presentation available beginning Monday, January 10 at 7:00 a.m. Eastern Time A live audio webcast of the J.P. Morgan presenta

  • GlobeNewswire

    Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)

    SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active g